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The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies
(mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors,
therapeutic mAbs present the potential to speciﬁcally target tumor cells and directly induce an immune response to lyse tumor
cells. Unique immune-eﬀector mechanisms are only triggered by therapeutic mAbs but not by small molecule targeting agents.
Although therapeutic murine mAbs or chimeric mAbs can cause immunogenicity, the advancement of genetic recombination for
humanizing rodent mAbs has allowed large-scale production and designation of mAbs with better aﬃnities, eﬃcient selection,
decreasing immunogenicity, and improved eﬀector functions. These advancements of antibody engineering technologies have
largely overcome the critical obstacle of antibody immunogenicity and enabled the development and subsequent Food and Drug
Administration (FDA) approval of therapeutic Abs for cancer and other diseases.
1.Introduction
Despite the landmark approval of the anti-CD20 mAb rit-
uximab for the treatment of B-cell malignancies, to date, no
mAb-based therapy has been approved for MM treatment.
ThedevelopmentofeﬀectivecytotoxicmAbtherapiesinMM
has been hindered by the lack of uniquely and constitutively
expressedtargetmoleculesonallMMcells.Indeed,studiesin
early 2000 demonstrated only minimal activity of anti-CD20
rituximab and antibodies against plasma cell-speciﬁc CD38
antibodiesinMM[1–4].However,numerouseﬀortstoiden-
tify new targets on MM cells including gene expression pro-
ﬁlingandoncogenomicstudiesareunderway.DerivedmAbs
(e.g., against CD40, HM1.24, IGF-1R, CD56, CS1, CD138,
CD74, IL-6R, CD38, TRAIL-R1, and the activin receptor
type IIA (ActRIIA)) have already demonstrated promising
preclinical as well as early clinical activity (Table 1).
Given the importance of the bone marrow (BM) mi-
croenvironment for MM cell growth, survival, and drug
resistance, mAbs have been additionally designed to func-
tionally block both autocrine and paracrine secreted
cytokines and growth factors as well as molecules mediating
MM-stromal cell interaction. For example, mAbs targeting
interleukin-6 (IL-6), vascular endothelial growth factor
(VEGF), Receptor Activator of NFκB ligand (RANKL) (also
known as osteoprotegerin ligand (OPGL)), and Dickkopf
homolog 1 (DKK1) are among those under clinical evalu-
ation. Speciﬁcally, targeting bone-MM cell interactions via
bone biology modulating factors such as DKK1 and RANKL
is likely to trigger anti-MM eﬀects but also improves bone
disease thereby improving both patient survival as well as
patient’s quality of life.
In the coming years, the preclinical progress in deﬁning
novel MM markers will be continued and subsequently will
advance the clinical development of therapeutic mAbs, alone
or in combination with other anti-MM agents, to improve
patient outcome in MM.
2. Mechanisms of Action of Therapeutic
Monoclonal Antibodies
Antibodies of IgG, the most commonly used immunoglob-
ulin form in cancer therapy, are unique proteins with dual
functionality. Therapeutic mAbs use one or more following
mechanisms (Figure 1) to reduce tumor burden in patients.2 Bone Marrow Research
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Apoptosis or
growth arrest
via
1.Blockade of receptor-
ligand interaction
2.Activation of apoptotic
signaling pathways
3. Speciﬁc targeting and
delivering immunotoxins
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Figure 1: Mechanisms of actions associated with therapeutic monoclonal antibodies. (a) Therapeutic antibodies could directly induce
apoptosis or growth arrest upon binding to cell surface antigen on tumor cells. Rituximab and Mapatumumab (anti-TRAIL-R1) could
inducegrowthinhibitionorapoptosissignalingtodirectlyblocktumorcellgrowthandsurvival.Suchmechanismofactionwasemployedby
mAbs conjugated with toxins, that is, maytansinoids (DM1, DM4) for BB-10901 (anti-CD56) and BT062 (anti-CD138), thus directly target
and eliminate tumor cells. Most of the approved therapeutic mAbs belong to IgG1 subclass, which has a long half-life and trigger potent
immune-eﬀector functions. (b) Following the binding of mAbs to a speciﬁc target on a tumor cells, antibody-dependent cellular cytotoxicity
(ADCC) is triggered by interactions between the Fc region of an antibody bound to a tumor cell and Fc receptors, particularly FcRI and
FcRIII, on immune eﬀector cells such as neutrophils, macrophages, and natural killer cells. MAb-coated tumor cells are phagocytosed by
macrophages or undergo cytolysis by NK cells. (c) In the case of complement-dependent cytotoxicity (CDC), recruitment of C1q by IgG
bound to the tumor cell surface is an obligatory ﬁrst step. This triggers a proteolytic cascade that leads to generation of the eﬀector molecule,
C3b, and then to formation of a membrane attack complex that kills the target cell by disrupting its cell membrane.
They can be categorized into direct and indirect actions.
Three modes of action could be further subcategorized from
the direct action (Figure 1(a)) of mAb-based cancer therapy,
including blocking the function of target signaling molecules
or receptors, stimulating apoptosis signaling cascades, and
targeting function to selectively target tumor cells and
deliver toxins. The receptor functional blocking can occur
by inhibiting ligand binding to inhibit cell cycle progression,
DNArepair,orangiogenesis.Itcouldalsooccurbyincreasing
internalizationofreceptorsordecreasingproteolyticcleavage
of receptors. In the case of targeting function, mAbs could
be conjugated with immunotoxins, that is, antitubulin
agents (DM1/DM4, auristatin), doxorubicin, radioisotopes,
or other chemotherapeutic drugs, thus selectively targeting
and killing tumor cells. Indirect action of mAb therapy is
mediated by the immune system. The elimination of tumor
cells using mAbs depends on Ig-mediated mechanisms,
including antibody-dependent cellular cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC), to activate
immune eﬀector cells to lyse target tumor cells (Figure 1(b))
These two mechanisms are believed to have the greatest
impact, although there are conﬂicting views of which of
these two pathways contributes the most to the response.
ADCC involves the recognition of the Ab by immune cells
that engage the Ab-marked cells and either through their
direct action, or through the recruitment of other cell types,
led to the tagged-cell’s death. CDC (Figure 1(c))i sap r o c e s s
w h e r eac a s c a d eo fd i ﬀerent complement proteins become
activated, usually when several IgGs are in close proximity
to each other, either with one direct outcome being cell lysis,
or one indirect outcome being attracting other immune cells
to this location for eﬀector cell function.
3.AntibodiesTargetingCellSurfaceProtein
on MM Cells
Several mAbs directed against MM cell surface are being
investigated as potential therapy in MM. Listed below are
mAbs against receptor antigens that are currently under
clinical development or investigation in MM.
3.1. Limited Clinical Beneﬁt from Anti-CD20 mAb Rituximab
in MM. MM is usually not considered as a disease suitable
for anti-CD20 therapy due to weak CD20 expression in the
majority of patients. For example, results from a clinical
phase II trial in relapsed MM showed that Rituximab
treatment yielded signiﬁcant reductions in circulating B cells
and serum IgM levels but had no beneﬁcial clinical eﬀect [5].
Moreover, rituximab was investigated for maintenance
therapy in MM following autologous hematopoietic stem
cell transplantation (SCT) [2]. Although the number of MM
patientswastoolowtodrawdeﬁnitiveconclusions,theuseof
rituximabinthissettingwasassociatedwithanunexpectedlyBone Marrow Research 7
highrateofearlyrelapse.Theauthorsthereforehypothesized
a possible role for rituximab in provoking a further decrease
in the residual, normal B-cell activity within the context of
the complex network of antitumor immune response. Taken
together, the resistance of MM cells against rituximab could
be due to the level of CD20 expression, dissociated action of
CDCandADCC,polymorphisminFGCR3(CD16)receptor,
and an inadequate dose schedule.
In contrast, other studies demonstrated that the CD20+
phenotype is associated with patients with t(11,14)(q13;q32)
and with shorter survival [6] and that occasional clinical
responses have been achieved in selected patients with
CD20+ myelomatous plasma cells [7, 8].
Finally, new insights suggest that circulating CD20+
clonotypic B cells act as precursors or “neoplastic stem cells”
in MM patients, representing the proliferative compartment
of the disease able to play a role in determining relapse after
eﬀective treatments [9]. Thus, clinical trials using rituximab
in MM may deserve further investigation.
3.2. Monoclonal Antibodies Targeting IL-6R to Overt IL-
6/IL-6R Function. IL-6 is a major growth and survival
factor in MM cells whose eﬀects are mainly paracrine [10].
VarioustherapeuticagentswhichaﬀectIL-6-mediatedeﬀects
have been tested including IL-6-conjugated mAbs directed
against IL-6R and IL-6 [11]. IL-6R antagonist SANT-7, in
combination with Dex and all-transretinoic acid (ATRA)
or zoledronic acid, strongly inhibited growth and induced
apoptosis in MM cells [12–14]. These studies suggest that
overcoming IL-6-mediated cell resistance by SANT-7 poten-
tiates the eﬀect of glucocorticoides and bisphosphonates
on MM cell growth and survival, providing a rationale for
therapies using IL-6 antagonists in MM.
Tocilizumab (MRA, atlizumab, Roche Pharmaceuticals)
isahumanizedanti-humanIL-6RmAb(rhPM-1,IgG1class)
designed by using genetic engineering technology and the
ﬁrst therapeutic mAb developed in Japan [15]. Tocilizumab
speciﬁcally blocks IL-6 actions and ameliorates diseases
associated with IL-6 overproduction [16]. For example,
besides Castleman’s disease and rheumatoid arthritis (RA),
tocilizumab has been shown to be eﬀective in patients
with juvenile idiopathic arthritis and Crohn’s disease [17,
18]. Tocilizumab treatment is generally well tolerated and
safe. Moreover, blockade of IL-6R may prove eﬀective in
limiting MM cell growth. Indeed it is now evaluated in
open-label Phase I (USA) and II (France) trials to assess
its safety and eﬃcacy as monotherapy in MM patients who
are not candidates for, or who have relapsed after stem cell
transplantation (SCT).
In addition, NRI, another receptor inhibitor of IL-6
genetically engineered from tocilizumab, is under preclinical
evaluation[19].NRIconsistsofVHandVLoftocilizumabin
a single-chain fragment format dimerized by fusing to the Fc
portion of human immunoglobulin G1. The binding activity
to IL-6R and the biological activity of the puriﬁed NRI
were found to be similar to those of parental tocilizumab.
Because NRI is encoded on a single gene, it is easily
applicable to a gene delivery system using virus vehicles. An
adenovirus vector encoding NRI was administered to mice
intraperitoneally (i.p.) and monitored for the serum NRI
levelandgrowthreductionpropertyonthexenograftedIL-6-
dependent MM cell line S6B45. These ﬁndings indicate that
NRI is a promising agent applicable to the therapeutic gene
delivery approach for IL-6-driven diseases.
3.3. Targeting CD40 by SGN-40 or HCD122. Novel mon-
oclonal antibodies targeting CD40 activation in MM cells,
SGN-40/Dacetuzumab (Seattle Genetics, Genentech) and
HCD122/Lucatumumab (Novartis), have been investigated
[20, 21]. In preclinical studies, SGN-40, a humanized IgG1
partial agonistic mAb mediates cytotoxicity against CD40-
expressing MM cell lines and patient MM cells via suppres-
sion of IL-6-induced proliferative and antiapoptotic eﬀects,
as well as ADCC [20]. SGN-40 also induced signiﬁcant
antitumor activity in xenograft mouse models of human
MM and lymphoma [22]. HCD122 (CHIR12.12) (Novartis),
an o v e l ,f u l l yh u m a n ,I g G 1 antagonistic mAb speciﬁcally
blocked CD40L-induced adhesion, cytokine secretion, and
survival of MM, as well as induced marked ADCC against
CD40+ MM cells [21]. In vivo anti-MM activity by HCD122
w a sd e m o n s t r a t e di nax e n o g r a f tm o d e lo f1 2 B MM Mp l a s -
macytoma in mice [23]. Early clinical trials have evaluated
the pharmacokinetics, safety, and eﬃcacy of dacetuzumab
monotherapy in patients with relapsed/refractory MM and
other B-cell tumors [24, 25]. Phase I data suggest both
agents are well tolerated with no immunogenicity and show
early evidence of single-agent clinical activity in relapsed and
refractory MM and NHL [26, 27]. SGN-40 Phase Ib clinical
trials in combination with lenalidomide and dexametha-
sone/or bortezomib are planned based on enhanced anti-
MM activities when combining SGN-40 with lenalidomide
[28].
3.4. Targeting CS1 by HuLuc63/Elotuzumab in MM. Using
subtractive hybridization of na¨ ıve B-cell cDNA from mem-
ory B/plasma cell cDNA, CS1 (CD2 subset-1, CRACC,
SLAMF7, CD319), a novel member of the signaling lympho-
cyte activating molecule- (SLAM-) related receptor family,
was identiﬁed to be highly expressed in plasma cells [29,
30]. Speciﬁcally, CS1 mRNA and protein are expressed in
CD138-puriﬁed primary tumor cells from the majority of
MM patients (>97%), but neither in major body organs
nor CD34+ stem cells. To a low extent, its expression was
also observed in NK cells, a subset of T cells, activated
monocytes and activated dendritic cells. CS1 may contribute
to MM pathogenesis by increasing MM cell adhesion,
clonogenic growth, and tumorigenicity via c-maf-mediated
interactions with BMSCs [31]. A novel humanized anti-
CS1 mAb HuLuc63 (elotuzumab) was selected for clinical
development due to its potent tumor-killing activity in vivo
and in vitro. Speciﬁcally, elotuzumab induced signiﬁcant
ADCC against MM cells even in the presence of BMSCs.
Moreover, it triggered autologous ADCC against primary
MM cells resistant to conventional or novel therapies
including bortezomib and HSP90 inhibitor, and markedly8 Bone Marrow Research
enhanced HuLuc63-induced MM cell lysis when pretreated
with conventional or novel anti-MM drugs [29, 32].
A phase I study of HuLuc63 was well tolerated in MM
patients [33]. Preliminary PK data reveal that peak serum
drug levels for the 0.5mg/kg dosing cohort reached 10
mg/mL, which was suﬃcient to achieve CS1 saturation of
at least 70% on the antigen rich NK cell subset. Drug
levels dropped below 1mg/mL by day 7, however, coinciding
with a decrease in saturation. This indicates that the higher
doses to be used in subsequent cohorts may achieve and
surpass sustained concentrations in patients above this
level. Enrollment is continuing to determine the MTD.
Early results of clinical trials of HuLuc63 in combination
with bortezomib or lenalidomide or dexamethasone were
reported at the ASH meeting 2009 [34, 35], suggesting that
elotuzumab may enhance the activity of bortezomib and
lenalidomide in treating MM with acceptable toxicity. PK
analysis suggests a serum half-life of 10-11 days at higher
doses (10 and 20mg/kg). Preliminary analysis of mononu-
clear cells of peripheral blood and the BM indicates that
objective responses correlate well with complete saturation
of CS1 sites by elotuzumab on BM plasma cells and NK cells.
The combination of elotuzumab with lenalidomide and low-
dose dexamethasone has a manageable adverse event proﬁle
and compared to historical data for lenalidomide and high-
dose dexamethasone, the preliminary eﬃcacy data (PR of
92%) are very encouraging.
3.5. Targeting CD56 with Immunotoxin-Conjugated mAb.
HuN901 conjugated with the maytansinoid N2 
-deacetyl-
N2 
-(3-mercapto-1-oxopropyl)-maytansine (DM1), a potent
antimicrotubularcytotoxicagentmayprovidetargeteddeliv-
ery of the drug to CD56-expressing tumors including MM.
HuN901-DM1 has signiﬁcant in vitro and in vivo anti-MM
activity at doses that were well tolerated in a murine model
[36].
The phase I clinical study of huN901-DM1 (BB-10901)
in 23MM patients determined the MTD as 140mg/m2/week
dose and demonstrated an overall favorable safety proﬁle
[37]. Exciting single agent activity was observed in heavily
pretreated MM patients, which warrant continued investiga-
tion of this novel agent in MM patients especially when used
in combination with approved anti-MM agents/regimens
such as lenalidomide and dexamethasone.
3.6. Targeting CD38 in Multiple Myeloma. The CD38
molecule is expressed on cell surfaces in a majority of lym-
phoid tumors, notably MM [38, 39]. However, early studies
using anti-CD38 mAb with or without an immunotoxin
(ricin) have not led to useful clinical applications [4, 40].
Recently,ahumananti-CD38IgG1 HuMax-CD38(Dara-
tumumab) was raised after immunizing transgenic mice
(HuMax-Mouse) possessing human, but not mouse, Ig
genes. Preclinical studies indicated that HuMax-CD38 was
eﬀective in killing primary CD38+CD138+ patient MM cells
and a range of MM/lymphoid cell lines by both ADCC and
CDC [41]. In SCID mouse animal models, using sensitive
bioluminescence imaging, treatment with Hu.
Max-CD38 inhibited CD38+ tumor cell growth in both
preventive and therapeutic settings. In addition, HuMax-
CD38 inhibits the CD38 ADP-ribosyl cyclase activity in
target cells, which may contribute to the eﬀectiveness of
HuMax-CD38 in killing both primary MM and plasma cell
leukemia cells.
Similarly, MOR202 (MorphoSysAG), a fully human anti-
CD38 IgG1 mAb produced by a human combinatorial
antibody library (HuCAL) platform, also eﬃciently triggers
ADCC against CD38+ MM cell lines and patient MM cells
in vitro as well as in vivo in a xenograft mouse model
[39, 42]. One practical problem in applying anti-CD38
therapy is the wide expression on lymphoid, myeloid, and
epithelial cells, especially following cell activation. However,
mAbs speciﬁcally blocking CD38 might still provide a new
approach for interfering with deleterious growth circuits,
therefore increasing the susceptibility of MM and leukemic
cells to conventional chemotherapy.
3.7. Targeting HM1.24 on MM Cells. HM1.24 (CD317) was
originally identiﬁed as a cell surface protein diﬀerentially
overexpressed on MM cells [43]a n dl a t e rw a sf o u n dt ob e
identical to bone stromal cell antigen 2 (BST-2). A role of
HM1.24intraﬃckingandsignalingbetweentheintracellular
and cell surface of MM cells was suggested since it is one of
the important activators of NF-kappaB pathway [44]. The
humanized anti-HM1.24 mAb (IgG1/kappa, AHM, Chugai
Pharmaceutical Co., Ltd.) is able to eﬀectively induce ADCC
againstsomehumanmyelomacellsinthepresenceofhuman
PBMCs as eﬀectively as a chimeric anti-HM1.24 mAb [45].
Single intravenous injection of AHM signiﬁcantly inhibited
tumor growth in both orthotopic and ectopic human MM
xenograft models [46]. Although limited, the only one phase
I/II clinical study reported that a humanized anti-HM1.24
mAb did not cause any serious toxicity when administered to
patients with relapsed or refractory MM [46].
Most recently, we characterized XmAb5592, a novel Fc-
engineered and humanized anti-HM1.24 mAb, and studied
mechanisms of its anti-MM activity [47]. XmAb5592, with
double amino acid substitution in Fc region of the wild-
type IgG1, has approximately 40-fold and 10-fold increases
in aﬃnity for Fc gamma receptor III (FcRIIIa) and (FcRIIa),
respectively, expressed on eﬀector cells including NK cells.
It triggers 10–100-fold higher ADCC against these MM cell
lines than a native/non-Fc-engineered version (anti-HM1.24
IgG1) of the Ab. XmAb5592 also induced more potent
anti-MM activity in murine subcutaneous xenograft murine
models using RPMI 8226 cells. These results suggest that
XmAb5592 is a promising next generation immunothera-
peutic for MM.
3.8. Targeting TRAIL Death Signaling Pathway. Two human
agonistic mAbs directed against TRAILR1 (HGS-ETR1,
TRM-1, Mapatumumab) and TRAILR2 (HGS-ETR2) killed
68% and 45% of MM cell lines, respectively, [48]. Only 18%
of MM cell lines are resistant to either antibody. There is no
correlation between TRAILR expression level and sensitivity
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(caspase 8, Bid) and the intrinsic (caspase 9) pathways
are activated by anti-TRAIL mAbs. Mapatumumab is well
tolerated in a phase I study in patients with advanced solid
malignancies (n = 41) and 12 patients had stable disease for
1.9 to 29.4 months [49]. These studies encouraged clinical
trials of anti-TRAILR1 mAb in MM. In addition, based on
enhanced cytotoxicity when combining mapatumumab with
bortezomib in preclinical experiments [50], a randomized
p h a s eI Is t u d yw a sr e c e n t l ys t a r t e dc o m p a r i n gT R M - 1p l u s
bortezomib (Velcade) versus bortezomib alone in patients
with relapsed or refractory MM.
3.9. Targeting CD74 with Milatuzumab. CD74 is an integral
membrane protein that functions as a MHC class II chap-
erone. Milatuzumab is a humanized anti-CD74 mAb con-
structed using the same human backbone as epratuzumab
(anti-CD22), whose safety has been demonstrated in clinical
trials of patients with B-cell malignancies and autoimmune
disorders [51, 52]. MM cell lines express CD74 (∼60%
of samples) and milatuzumab caused growth inhibition
and induction of apoptosis in CD74-expressing MM cell
lines when cross-linked with an anti-human immunoglob-
ulin G secondary antibody [53]. Moreover milatuzumab
demonstratedpromisingtherapeuticactivityinaCAG-SCID
mouse model of disseminated disease for MM when used
alone or in combination with doxorubicin, dexamethasone,
bortezomib, or lenalidomide [54, 55]. In a phase I trial,
milatuzumab showed no severe adverse eﬀects in patients
with relapsed/refractory MM, and it stabilized the disease
in some patients for up to 12 weeks [51]. Supporting
the data in MM ongoing clinical trials testing diﬀerent
treatment schedules of milatuzumab in chronic lymphocytic
leukemia, non-Hodgkin’s lymphoma, and MM indicate that
milatuzumab shows no severe adverse eﬀects in humans.
4.AntibodiesTargetingMMCellsinthe Bone
Marrow Microenvironment
MM cells are highly dependent on the BM microen-
vironment for growth and survival through interactions
particularly with BM stromal cells (BMSCs) and osteoclasts,
which secrete important MM growth factors and cytokines.
Importantly, these factors/cytokines are further induced
from BMSCs when MM cells adhere to BMSCs [10]. Thus,
mAbs designed to block the binding of MM cell growth and
survival factors to their cognate receptors have been under
intensive development.
4.1. Blockage of IL-6 Binding to MM Cells. Early work
in developing mAb-based immunotherapies for MM has
been focused on the blockade of IL-6 secretion from BM
microenvironment because of its key role in promoting MM
cell growth and survival. Initial studies of mouse mAb to IL-
6 (murine BE-4 and BE-8) demonstrated a transient tumor
cytostasis and reduction in toxicities from IL-6 [56]. The
potential of combination therapy, including BE-8 (250mg),
Dex (49mg/day), and high-dose melphalan (220mg/m2
(HDM220)), followed by autologous SCT was demonstrated
for the treatment of 16 patients with advanced MM. Overall,
13 of 16 patients (81.3%) exhibited a response, with a
complete response (CR) seen in 6 patients (37.5%) without
any toxic or allergic reactions. However, the incidence of
thrombocytopenia and neutropenia increased. Subsequent
clinical trials of BE-8 concluded that limitations of this
regimen are ﬁrst the amount of BE-8 that can be injected
due to its short half-life (3-4 days) and second, the continued
production of IL-6 in vivo. Most recently, a high-aﬃnity fully
human version of BE-8, OP-R003-1 (or 1339, Azintrel), was
selected through ActivMAb antibody discovery technology.
Indeed, it enhanced cytotoxicity induced by dexamethasone,
as well as bortezomib, lenalidomide, and perifosine, in a
synergistic fashion [57]. Importantly, Azintrel also blocked
bone turnover in SCID-hu mouse model of MM, providing
an additional rationale for its use in MM.
Despite overcoming the safety concerns of human anti-
mouseantibodiesassociatedwithmurineanti-IL-6mAband
a long half-life (17.8 days) in circulation, the chimeric mouse
mAb to IL-6 CNTO 328 has been ineﬀective in producing
a meaningful response in MM [58, 59]. Nevertheless, due
to enhanced anti-MM activities of combined CNTO 328
and bortezomib/or dexamethasone in preclinical models,
ongoing studies are investigating these regimens for their
clinical value in treating MM [60, 61]. Speciﬁcally, results
of a small safety analysis (n = 21) done as a run-in to a
larger ongoing Phase II trial showed promising preliminary
eﬃcacy of CNTO 328 in combination with bortezomib in
relapsed/refractory MM. CNTO 328 is also being evaluated
as part of a combination therapy for initial treatment of MM
in aPhaseIItrialwhichcomparesthesafetyand eﬀectiveness
of CNTO 328 plus Velcade-melphalan-prednisone (VMP)
with VMP alone.
4.2. Targeting MM-Induced Bone Lesion
4.2.1. Targeting RANK/RANKL/OPG Axis Using Denosumab
for MM-Associated Bone Destruction. Receptor activator of
nuclear factor-kappaB ligand (RANKL) is a cytokine mem-
ber of the tumor necrosis factor family that is the principal
mediator of osteoclastic bone resorption [62]. Osteoprote-
gerin (OPG), a natural soluble decoy receptor of RANKL,
modulates the eﬀe c to fR A N K La n di sa b l et op r e v e n te x c e s -
sive bone resorption in the normal state. RANKL expression
is elevated in patients with MM [63, 64]. Denosumab (AMG
162, Amgen Inc., Thousand Oaks, CA) is an investigational
f u l l yh u m a nm A bw i t hh i g ha ﬃnity and speciﬁcity for
RANKL that mimics the natural bone-protecting actions of
OPG [65]. A phase 1 clinical trial in patients with MM (n =
25) or breast cancer with bone metastases (n = 29) showed
that following a single s.c. dose of denosumab (0.1, 0.3, 1.0,
or 3.0mg/kg), levels of urinary and serum N-telopeptide
decreased within 1 day, and this decrease lasted through 84
days at the higher denosumab doses [66]. Mean half-lives
of denosumab were 33.3 and 46.3 days for the two highest
dosages. Larger trials are ongoing to investigate the eﬀect of
denosumabforthetreatmentofcancer-inducedbonedisease
and other bone loss disorders [67].10 Bone Marrow Research
4.2.2. Targeting the Wnt Inhibitor Dickkopf-1 (DKK-1).
Dickkopf-1 (DKK1), a soluble inhibitor of wingless (Wnt)
signaling secreted by MM cells contributes to osteolytic
bone disease by inhibiting the diﬀerentiation of osteoblasts.
The eﬀect of anti-DKK1 mAb on bone metabolism and
tumor growth in a SCID-rab system has been evaluated
[68]. The implants of control animals showed signs of
MM-induced resorption, whereas mice treated with anti-
DKK1 antibodies blunted resorption and improved the bone
mineral density of the implants. Histologic examination
revealedthatmyelomatousbonesofanti-DKK1-treatedmice
had increased numbers of osteocalcin-expressing osteoblasts
and reduced number of multinucleated TRAP-expressing
osteoclasts. The bone anabolic eﬀect of anti-DKK1 was
associated with reduced MM burden (P<. 04). Anti-
DKK1 also signiﬁcantly increased BMD of the implanted
bone and murine femur in nonmyelomatous SCID-rab
mice, suggesting that DKK1 is physiologically an important
regulator of bone remodeling in adults. Anti-DKK1 agents
including BHQ880 (Novartis) may therefore represent the
next generation of therapeutic options for the enhancement
of bone repair in some malignant and degenerative bone
diseases including MM [69, 70]. Although BHQ880 had
no direct eﬀect on MM cell growth, BHQ880 increased
osteoblast diﬀerentiation, neutralized the negative eﬀect of
MM cells on osteoblastogenesis, and reduced IL-6 secretion.
Furthermore, in a SCID-hu murine model of human MM,
BHQ880 treatment led to a signiﬁcant increase in osteoblast
number, serum human osteocalcin level, and trabecular
bone.PreliminaryresultsfromaphaseI/IItrialinMMwhere
BHQ880 was given IV for 28 days was well tolerated when
given in combination with zoledronic acid.
4.2.3. Targeting the Activin Receptor Type IIA (ActRIIA).
ACE-011, a novel bone anabolic agent currently in a Phase
2 clinical trial in MM, is a protein therapeutic based on
the activin receptor IIA. In numerous preclinical models
of bone loss, ACE-011 has demonstrated beneﬁcial eﬀects
on both trabecular and cortical bone [71, 72]. ACE-011
increased bone mineral density, improved bone architecture,
increased the mineral apposition and bone formation rates,
and improved bone mechanical strength [73]. Results of the
Phase 1 study in postmenopausal women demonstrated that
a single dose of ACE-011 caused a rapid, sustained, dose-
dependent increase in serum levels of bone-speciﬁc alkaline
phosphatase (BSAP), a marker of bone formation, while
a marker of bone resorption, C-terminal type 1 collagen
telopeptide (CTX), decreased. In MM an ongoing multi-
center Phase 2 trial is conducted in Russian patients which
are treated with melphalan, prednisone, and thalidomide
and randomized to receive either monthly doses of ACE-
011 or placebo for up to three months. Preliminary results
show clinical signiﬁcant increases in biomarkers of bone
formation, improvement in skeletal metastases, decreases in
bone pain as well as antitumor activity [54]. In summary,
these data indicate that ACE-011 is well tolerated and has
signiﬁcant hematologic activity in MM patients receiving
myelosuppressive chemotherapy.
Moreover, ACE-011 has potential as a novel therapy
for chemotherapy-induced anemia and may be an eﬀective
alternative to erythropoietin- (EPO-) based treatments.
4.3. Targeting Angiogenesis by VEGF Inhibitor Bevacizumab
(Avastin). Vascular endothelial factor (VEGF) is important
for the formation of new blood vessels and plays a key role
not only in solid tumors but also in hematologic malignan-
cies, including MM [74]. Bevacizumab targets and blocks
VEGF and VEGF’s binding to its receptor on the vascular
endothelium [75]. Anti-VEGF Abs were active alone, and in
combination with radiation in earlier preclinical studies [75,
76]. It is currently being studied clinically in many solid and
blood tumors including primary systemic amyloidosis and
MM [77, 78]. NCI’s Cancer Therapy Evaluation Program is
sponsoringaphaseIIstudyofbevacizumabplusthalidomide
in MM [78].
4.4. Targeting BAFF/ARPIL Growth and Survival Pathway
by Atacicept (TACI-Ig) or BAFF Inhibitor. Recently, B-cell
activating factor of the tumor necrosis factor (TNF) family
(BAFF; also known as B lymphocyte stimulator, BLyS) and
a proliferation inducing ligand (APRIL), were identiﬁed
as new survival factors for MM [79–81]. In addition to
BMSCs, osteoclasts produce these factors to support MM
cells in the BM microenvironment [81, 82]. Their cognate
receptors are BAFF-R/BR3, transmembrane activator and
calcium modulator (TACI), and B-cell maturation antigen
(BCMA) with heterogeneous expression among patient MM
cells. Speciﬁcally, RNA expression of BCMA and TACI is
approximately >30-fold and >10-fold higher, respectively,
than that of BR3 [81]. BR3 speciﬁcally binds BAFF but
not APRIL, and has very limited expression in mature B-
cells plasma cells [83]. In fact, BCMA expression is only
acquired in mature B cells and accompanied by loss of BAFF-
R expression [83], suggesting a key role of BCMA in plasma
cell survival. These studies provide clinical rationale to target
BAFF/APRIL survival pathway in MM.
Atacicept (TACI-Ig, ZymoGenetics; Serono) acts as a
decoy receptor by binding to and neutralizing soluble BAFF
and APRIL, and preventing these ligands from binding to
their cognate receptors on B-cell tumors, thereby enhancing
cytotoxicity. An open-label, dose-escalation Phase I/II study
enrolled 16 patients with refractory or relapsed MM (n =
12) or active, progressive Waldenstrom’s Macroglobulinemia
(n = 4)[84].Ataciceptwaswelltoleratedandshowedclinical
and biological activity consistent with its mechanism of
action. TACI was expressed heterogeneously among patient
MM cells, which may explain promising results for the
treatment of TACIhigh MM cells in a trial for atacicept [84,
85].
In addition, the in vivo antitumor activity of neutralizing
anti-BAFF mAb in SCID-hu model of human MM provide
the preclinical rationale for its evaluation in the treatment
of MM [86]. Moreover, since all MM cell lines and patient
MM cells express BCMA, BCMA might be a promising
target for monoclonal antibody development against MM.
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due to graft-versus-tumor response have donor derived anti-
BCMA Abs that are tumor lytic in vivo [87]. Thus, BCMA is
a target of donor B-cell immunity in patients with myeloma
who respond to donor lymphocyte infusion (DLI). Antibody
responses to cell-surface BCMA may contribute directly to
tumor rejection in vivo. Indeed, BCMA antibodies show
cytotoxic activity both as naked IgG and as drug conjugates,
which warrant further evaluation as therapeutic candidates
for plasma cell malignancies [88].
4.5. Other Potential Targets. Additional mAbs are directed
against a variety of further MM cell targets including HLA-
DR by 1D09C3 [89], HLA-class I by 2D7-DB [90], kininogen
byC11C1[91],andpolyclonalrabbitantithymocyteglobulin
(rATG) [92].
Finally, since NK cells play a critical role in ADCC to lyse
tumortargetcellsviatherapeuticmonoclonalantibodiesand
inhibitory-cell killer immunoglobulin-like receptors (KIRs)
negatively regulate natural killer (NK) cell-mediated killing
of HLA class I-expressing tumors, mAbs targeting KIR
might prevent their inhibitory signaling leading to enhanced
ADCC. A novel fully human anti-KIR blocking mAb, 1-
7F9 (or IPH 2101), antagonizes inhibitory KIR signaling,
activates NK cells and augments natural killer-mediated
killing of tumor cells [93, 94]. Importantly, 1-7F9 enhances
patient NK cell cytotoxicity against autologous MM tumor
cells in vitro and appears safe in an ongoing phase I clinical
trial [95]. A multicenter, open label Phase IIa clinical trial
(trial IPH 2101-201, in France) has started to evaluate IPH
2101 as a single agent in patients with stable measurable
MM after induction therapy. Another phase II clinical trial
to assess the potential of lenalidomide combined with 1-7F9
will be initiated in patients with MM.
5. Conclusion
For the past decade, more than a dozen of therapeutic
mAbs have either entered clinical trials or in clinical devel-
opment in MM. However, mAbs targeting myeloma cells
have not yet been included as part of standard myeloma
therapy. Although the ability to create essentially human
antibody structures has reduced the likelihood of host-
protective immune responses that otherwise limit the utility
oftherapy,majorityofMMpatientsareimmunosuppressive.
The immediate goal would be testing next generations of
genetically Fc-engineered mAbs that not only binds to target
MM antigens with high aﬃnity but also have superior
interaction (>1log) with host immune eﬀectors. A better
understanding of the immune defects that prevent MM
patients from mounting a strong response against their
tumor cells should also improve establishment of eﬀective
mAb-based immunotherapy strategies for MM. We expect
that, the use of potentially targeted therapies by mAbs, such
as Fc-engineered naked or immunoconjugate or bispeciﬁc
would soon claim deﬁned therapeutic roles in patients with
MM.Thefavorabletoxicityproﬁleoftumor-targetedtherapy
by mAbs, unlike other forms of therapy, may allow the main-
tenance of quality of life, while eﬃciently attack the tumors.
References
[1] S. P. Treon, Y. Shima, M. L. Grossbard et al., “Treatment of
multiple myeloma by antibody mediated immunotherapy and
induction of myeloma selective antigens,” Annals of Oncology,
vol. 11, no. 1, pp. S107–S111, 2000.
[2] C.Gemmel,F.W.Cremer,M.Weisetal.,“Anti-CD20antibody
as consolidation therapy in a patient with primary plasma
cell leukemia after high-dose therapy and autologous stem cell
transplantation,”AnnalsofHematology,vol.81,no.2,pp.119–
123, 2002.
[3] P. Musto, A. M. Carella Jr., M. M. Greco et al., “Short
progression-free survival in myeloma patients receiving rit-
uximab as maintenance therapy after autologous transplanta-
tion,” British Journal of Haematology, vol. 123, no. 4, pp. 746–
747, 2003.
[4] J. H. Ellis, K. A. Barber, A. Tutt et al., “Engineered anti-
CD38 monoclonal antibodies for immunotherapy of multiple
myeloma,” JournalofImmunology,vol.155,no.2,pp.925–937,
1995.
[ 5 ]N .Z o j e r ,K .K i r c h b a c h e r ,M .V e s e l y ,W .H¨ ubl, and H. Ludwig,
“Rituximab treatment provides no clinical beneﬁt in patients
with pretreated advanced multiple myeloma,” Leukemia and
Lymphoma, vol. 47, no. 6, pp. 1103–1109, 2006.
[6] N. Robillard, H. Avet-Loiseau, R. Garand et al., “CD20 is
associated with a small mature plasma cell morphology and
t(11;14) in multiple myeloma,” Blood, vol. 102, no. 3, pp.
1070–1071, 2003.
[7] A. Gozzetti, A. Fabbri, S. Lazzi, M. Bocchia, and F. Lauria,
“Reply to Rituximab activity in CD20 positive multiple
myeloma,” Leukemia, vol. 21, no. 8, pp. 1842–1843, 2007.
[8] S. Hofer, S. Hunziker, S. Dirnhofer, and C. Ludwig, “Rit-
uximab eﬀective in a patient with refractory autoimmune
haemolytic anaemia and CD20-negative multiple myeloma,”
British Journal of Haematology, vol. 122, no. 4, pp. 690–691,
2003.
[9] C. A. Huﬀ and W. Matsui, “Multiple myeloma cancer stem
cells,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2895–
2900, 2008.
[10] T. Hideshima, C. Mitsiades, G. Tonon, P. G. Richardson,
and K. C. Anderson, “Understanding multiple myeloma
pathogenesis in the bone marrow to identify new therapeutic
targets,” Nature Reviews Cancer, vol. 7, no. 8, pp. 585–598,
2007.
[11] M. Trikha, R. Corringham, B. Klein, and J. F. Rossi, “Targeted
anti-interleukin-6 monoclonal antibody therapy for cancer: a
review of the rationale and clinical evidence,” Clinical Cancer
Research, vol. 9, no. 13, pp. 4653–4665, 2003.
[12] D. Honemann, M. Chatterjee, R. Savino et al., “The IL-6
receptor antagonist SANT-7 overcomes bone marrow stromal
cell-mediated drug resistance of multiple myeloma cells,”
International Journal of Cancer, vol. 93, no. 5, pp. 674–680,
2001.
[13] P. Tassone, S. Forciniti, E. Galea et al., “Synergistic induction
of growth arrest and apoptosis of human myeloma cells by the
IL-6 super-antagonist Sant7 and Dexamethasone,” Cell Death
and Diﬀerentiation, vol. 7, no. 3, pp. 327–328, 2000.
[14] P. Tassone, E. Galea, S. Forciniti, P. Tagliaferri, and S. Venuta,
“The IL-6 receptor super-antagonist Sant7 enhances antipro-
liferative and apoptotic eﬀects induced by dexamethasone
and zoledronic acid on multiple myeloma cells,” International
Journal of Oncology, vol. 21, no. 4, pp. 867–873, 2002.12 Bone Marrow Research
[15] S. L. Plushner, “Tocilizumab: an interleukin-6 receptor inhib-
itor for the treatment of rheumatoid arthritis,” Annals of Phar-
macotherapy, vol. 42, no. 11, pp. 1660–1668, 2008.
[16] J. Kanda, H. Kawabata, Y. Yamaji et al., “Reversible car-
diomyopathyassociatedwithmulticentricCastlemandiseases:
successful treatment with tocilizumab, an anti-interleukin 6
receptor antibody,” International Journal of Hematology, vol.
85, no. 3, pp. 207–211, 2007.
[17] N. Nishimoto, “Clinical studies in patients with Castleman’s
disease, Crohn’s disease, and rheumatoid arthritis in Japan,”
Clinical Reviews in Allergy and Immunology, vol. 28, no. 3, pp.
221–229, 2005.
[18] P. Woo, N. Wilkinson, A. M. Prieur et al., “Open label phase II
trial of single, ascending doses of MRA in Caucasian children
with severe systemic juvenile idiopathic arthritis: proof of
principle of the eﬃcacy of IL-6 receptor blockade in this
type of arthritis and demonstration of prolonged clinical
improvement,” Arthritis Research & Therapy,v o l .7 ,n o .6 ,p p .
R1281–R1288, 2005.
[19] N. Yoshio-Hoshino, Y. Adachi, C. Aoki, A. Pereboev, D.
T. Curiel, and N. Nishimoto, “Establishment of a new
interleukin-6 (IL-6) receptor inhibitor applicable to the gene
therapy for IL-6-dependent tumor,” Cancer Research, vol. 67,
no. 3, pp. 871–875, 2007.
[20] Y. T. Tai, L. P. Catley, C. S. Mitsiades et al., “Mechanisms
by which SGN-40, a humanized anti-CD40 antibody, induces
cytotoxicity in human multiple myeloma cells: clinical impli-
cations,” Cancer Research, vol. 64, no. 8, pp. 2846–2852, 2004.
[21] Y. T. Tai, X. Li, X. Tong et al., “Human anti-CD40 antagonist
antibodytriggerssigniﬁcantantitumoractivityagainsthuman
multiple myeloma,” Cancer Research, vol. 65, no. 13, pp. 5898–
5906, 2005.
[22] C. L. Law, K. A. Gordon, J. Collier et al., “Preclinical anti-
lymphoma activity of a humanized anti-CD40 monoclonal
antibody, SGN-40,” Cancer Research, vol. 65, no. 18, pp. 8331–
8338, 2005.
[23] L. Long, X. Tong, M. Patawaran et al., “Antagonist anti-CD40
antibody CHIR-12.12 causes tumor regression and prolongs
survival in multiple myeloma xenograft models,” IMF Oral
Presentation and Abstract, no. 3, 2005.
[24] W. Bensinger, S. Jagannath, P. S. Becker et al., “A phase 1
dose escalation study of a fully human, antagonist anti-CD40
antibody, HCD 122 (formerly CHIR-12.12), in patients with
relapsed and refractory multiple myeloma,” Blood, vol. 108,
2006, abstract no. 3675.
[25] M. A. Hussein, J. R. Berenson, R. Niesvizky et al., “Results
of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients
with relapsed multiple myeloma,” Blood, vol. 108, article 3576,
2006.
[26] S. Khubchandani, M. S. Czuczman, and F. J. Hernandez-
Ilizaliturri, “Dacetuzumab, a humanized mAb against CD40
for the treatment of hematological malignancies,” Current
Opinion in Investigational Drugs, vol. 10, no. 6, pp. 579–587,
2009.
[27] R. Advani, A. Forero-Torres, R. R. Furman et al., “Phase
I study of the humanized anti-CD40 monoclonal antibody
dacetuzumab in refractory or recurrent non-Hodgkin’s lym-
phoma,”JournalofClinicalOncology,vol.27,no.26,pp.4371–
4377, 2009.
[28] Y. T. Tai, X. F. Li, L. Catley et al., “Immunomodulatory drug
lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-
40-induced cytotoxicity in human multiple myeloma: clinical
implications,” Cancer Research, vol. 65, no. 24, pp. 11712–
11720, 2005.
[29] Y. T. Tai, M.Dillon, W. Song et al., “Anti-CSlhumanized mon-
oclonalantibodyHuLuc63inhibitsmyelomacelladhesionand
induces antibody-dependent cellular cytotoxicity in the bone
marrow milieu,” Blood, vol. 112, no. 4, pp. 1329–1337, 2008.
[30] E. D. Hsi, R. Steinle, B. Balasa et al., “CS1, a potential new
therapeutic antibody target for the treatment of multiple
myeloma,” Clinical Cancer Research, vol. 14, no. 9, pp. 2775–
2784, 2008.
[31] Y. T. Tai, E. Soydan, W. Song et al., “CS1 promotes multiple
myeloma cell adhesion, clonogenic growth, and tumorigenic-
ityviac-maf-mediatedinteractionswithbonemarrowstromal
cells,” Blood, vol. 113, no. 18, pp. 4309–4318, 2009.
[32] F. van Rhee, S. M. Szmania, M. Dillon et al., “Combina-
torial eﬃcacy of anti-CS1 monoclonal antibody elotuzumab
(HuLuc63) and bortezomib against multiple myeloma,”
Molecular Cancer Therapeutics, vol. 8, no. 9, pp. 2616–2624,
2009.
[33] W. Bensinger, J. Zonder, S. Singhal et al., “Phase I trial of
HuLuc63 in multiple myeloma,” Blood, vol. 110, 2007.
[34] A. J. Jakubowiak, W. Bensinger, D. Siegel et al., “Phase 1/2
study of elotuzumab in combination with bortezomib in
patients with multiple myeloma with one to three prior
therapies: interim results,” Blood, vol. 114, article 3876, 2009.
[35] S. Lonial, R. Vij, J.-L. Harousseau et al., “Phase 1/2 study of
elotuzumab in combination with lenalidomide and low dose
dexamethasone in relapsed or refractory multiple myeloma:
interim results,” Blood, vol. 114, article 432, 2009.
[36] P. Tassone, A. Gozzini, V. Goldmacher et al., “In vitro
and in vivo activity of the maytansinoid immunocon-
jugate huN901-N2 -deacetyl-N2 -(3-mercapto-1-oxopropyl)-
maytansine against CD56+ multiple myeloma cells,” Cancer
Research, vol. 64, no. 13, pp. 4629–4636, 2004.
[37] A. Chanan-Khan, J. Wolf, M. Gharibo et al., “Phase I study
of IMGN901, used as monotherapy, in patients with heavily
pre-treated CD56-positive multiple myeloma—a preliminary
safety and eﬃcacy analysis,” Blood, vol. 114, article 2883, 2009.
[38] F.K.Stevenson,A.J.Bell,R.Cusacketal.,“Preliminarystudies
for an immunotherapeutic approach to the treatment of
human myeloma using chimeric anti-CD38 antibody,” Blood,
vol. 77, no. 5, pp. 1071–1079, 1991.
[39] G. T. Stevenson, “CD38 as a therapeutic target,” Molecular
Medicine, vol. 12, no. 11-12, pp. 345–346, 2006.
[ 4 0 ]V .S .G o l d m a c h e r ,L .A .B o u r r e t ,B .A .L e v i n ee ta l . ,“ A n t i -
CD38-blocked ricin: an immunotoxin for the treatment of
multiple myeloma,” Blood, vol. 84, no. 9, pp. 3017–3025, 1994.
[41] Y. T. Tai, M. de Weers, X. Li et al., “Daratumumab, a novel
potent human anti-CD38 monoclonal antibody, induces sig-
niﬁcantkillingofhumanmultiplemyelomacells,” Therapeutic
Implication, vol. 114, article 608, 2009.
[42] M. Tesar, “Fully human antibody MOR202 against CD38 for
the treatment of multiple myeloma and other blood-borne
malignancies,” Journal of Clinical Oncology, vol. 25, article
8106, 2007.
[43] S. Ozaki, M. Kosaka, S. Wakatsuki, M. Abe, Y. Koishihara, and
T. Matsumoto, “Immunotherapy of multiple myeloma with
a monoclonal antibody directed against a plasma cell-speciﬁc
antigen, HM1.24,” Blood, vol. 90, no. 8, pp. 3179–3186, 1997.
[44] A.Matsuda,Y.Suzuki,G.Hondaetal.,“Large-scaleidentiﬁca-
tion and characterization of human genes that activate NF-κB
and MAPK signaling pathways,” Oncogene, vol. 22, no. 21, pp.
3307–3318, 2003.Bone Marrow Research 13
[45] S. Ozaki, M. Kosaka, Y. Wakahara et al., “Humanized anti-
HM1.24 antibody mediates myeloma cell cytotoxicity that is
enhanced by cytokine stimulation of eﬀector cells,” Blood, vol.
93, no. 11, pp. 3922–3930, 1999.
[46] S. Kawai, Y. Yoshimura, S. I. Iida et al., “Antitumor activity
of humanized monoclonal antibody against HM1.24 antigen
in human myeloma xenograft models,” Oncology Reports, vol.
15, no. 2, pp. 361–367, 2006.
[47] Y.T.Tai,U.Muchhal,X.Lietal.,“XmAb5592Fc-engineered
humanized anti-HM1.24 monoclonal antibody has potent in
vitro and in vivo eﬃcacy against multiple myeloma,” Blood,
vol. 114, article 609, 2009.
[48] E. Menoret, P. Gomez-Bougie, A. Geﬀroy-Luseau et al.,
“Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-
mediated apoptosis induced by HGS-ETR1 and HGS-ETR2
human mAbs in myeloma cells,” Blood, vol. 108, no. 4, pp.
1346–1352, 2006.
[49] S. J. Hotte, H. W. Hirte, E. X. Chen et al., “A phase 1 study of
mapatumumab(fullyhumanmonoclonalantibodytoTRAIL-
R1) in patients with advanced solid malignancies,” Clinical
Cancer Research, vol. 14, no. 11, pp. 3450–3455, 2008.
[50] M. R. Smith, F. Jin, and I. Joshi, “Bortezomib sensitizes non-
Hodgkin’s lymphoma cells to apoptosis induced by antibodies
to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) receptors TRAIL-R1 and TRAIL-R2,” Clinical Cancer
Research, vol. 13, no. 18, part 2, pp. 5528s–5534s, 2007.
[51] Z. Berkova, R. H. Tao, and F. Samaniego, “Milatuzumab-a
promising new immunotherapeutic agent,” Expert Opinion on
Investigational Drugs, vol. 19, no. 1, pp. 141–149, 2010.
[52] R. Stein, M. J. Mattes, T. M. Cardillo et al., “CD74: a new
candidate target for the immunotherapy of B-cell neoplasms,”
Clinical Cancer Research, vol. 13, no. 18, part 2, pp. 5556s–
5563s, 2007.
[53] J. D. Burton, S. Ely, P. K. Reddy et al., “CD74 is expressed
by multiple myeloma and is a promising target for therapy,”
Clinical Cancer Research, vol. 10, no. 19, pp. 6606–6611, 2004.
[ 5 4 ]K .M .A b d u l k a d y r o v ,G .N .S a l o g u b ,N .K .K h u a z h e v ae t
al., “ACE-011, a soluble activin receptor type Iia IgG-Fc
fusionprotein,increaseshemoglobin(Hb)andimprovesbone
lesions in multiple myeloma patients receiving myelosup-
pressive chemotherapy: preliminary analysis,” Blood, vol. 114,
article 749, 2009.
[55] R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Gold-
enberg, “Combining milatuzumab with bortezomib, dox-
orubicin, or dexamethasone improves responses in multiple
myeloma cell lines,” Clinical Cancer Research, vol. 15, no. 8,
pp. 2808–2817, 2009.
[56] P. Moreau, J. L. Harousseau, J. Wijdenes, N. Morineau, N.
Milpied, and R. Bataille, “A combination of anti-interleukin
6 murine monoclonal antibody with dexamethasone and
high-dose melphalan induces high complete response rates in
advanced multiple myeloma,” British Journal of Haematology,
vol. 109, no. 3, pp. 661–664, 2000.
[57] M. Fulciniti, T. Hideshima, C. Vermot-Desroches et al.,
“A high-aﬃnity fully human anti-IL-6 mAb, 1339, for the
treatment of multiple myeloma,” Clinical Cancer Research, vol.
15, no. 23, pp. 7144–7152, 2009.
[ 5 8 ]H .C .T .v a nZ a a n e n ,H .M .L o k h o r s t ,L .A .A a r d e n ,H .J .A .
M. Rensink, S. O. Warnaar, and M. H. J. van Oers, “Blocking
interleukin-6activitywithchimericanti-IL6monoclonalanti-
bodies in multiple myeloma: eﬀects on soluble IL6 receptor
and soluble gp130,” Leukemia and Lymphoma, vol. 31, no. 5-6,
pp. 551–558, 1998.
[59] H. C. T. van Zaanen, H. M. Lokhorst, L. A. Aarden et al.,
“Chimaeric anti-interleukin 6 monoclonal antibodies in the
treatment of advanced multiple myeloma: a phase I dose-
escalating study,” British Journal of Haematology, vol. 102, no.
3, pp. 783–790, 1998.
[60] P. M. Voorhees, Q. Chen, D. J. Kuhn et al., “Inhibition of
interleukin-6 signaling with CNTO 328 enhances the activity
of bortezomib in preclinical models of multiple myeloma,”
Clinical Cancer Research, vol. 13, no. 21, pp. 6469–6478, 2007.
[61] P. M. Voorhees, Q. Chen, G. W. Small et al., “Targeted
inhibition of interleukin-6 with CNTO 328 sensitizes pre-
clinical models of multiple myeloma to dexamethasone-
mediated cell death,” British Journal of Haematology, vol. 145,
no. 4, pp. 481–490, 2009.
[62] E. M. Lewiecki, “RANK ligand inhibition with denosumab for
themanagementofosteoporosis,”ExpertOpiniononBiological
Therapy, vol. 6, no. 10, pp. 1041–1050, 2006.
[63] E. Terpos, R. Szydlo, J. F. Apperley et al., “Soluble receptor
activator of nuclear factor κB ligand-osteoprotegerin ratio
predicts survival in multiple myeloma: proposal for a novel
prognostic index,” Blood, vol. 102, no. 3, pp. 1064–1069, 2003.
[64] N. Giuliani, R. Bataille, C. Mancini, M. Lazzaretti, and S.
Barill´ e, “Myeloma cells induce imbalance in the osteopro-
tegerin/osteoprotegerin ligand system in the human bone
marrow environment,” Blood, vol. 98, no. 13, pp. 3527–3533,
2001.
[65] J. S. Burkiewicz, S. L. Scarpace, and S. P. Bruce, “Denosumab
in osteoporosis and oncology,” Annals of Pharmacotherapy,
vol. 43, no. 9, pp. 1445–1455, 2009.
[ 6 6 ]J .J .B o d y ,T .F a c o n ,R .E .C o l e m a ne ta l . ,“ As t u d yo f
the biological receptor activator of nuclear factor-κB ligand
inhibitor, denosumab, in patients with multiple myeloma or
bone metastases from breast cancer,” Clinical Cancer Research,
vol. 12, no. 4, pp. 1221–1228, 2006.
[67] D. Santini, M. E. Fratto, B. Vincenzi et al., “Denosumab: the
era of targeted therapies in bone metastatic diseases,” Current
Cancer Drug Targets, vol. 9, no. 7, pp. 834–842, 2009.
[68] S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and
J. D. Shaughnessy, “Antibody-based inhibition of DKK1
suppresses tumor-induced bone resorption and multiple
myeloma growth in vivo,” Blood, vol. 109, no. 5, pp. 2106–
2111, 2007.
[69] D. J. Heath, A. D. Chantry, C. H. Buckle et al., “Inhibiting
dickkopf-1 (Dkkl) removes suppression of bone formation
and prevents the development of osteolytic bone disease in
multiple myeloma,” Journal of Bone and Mineral Research, vol.
24, no. 3, pp. 425–436, 2009.
[70] M. Fulciniti, P. Tassone, T. Hideshima et al., “Anti-DKK1
mAb (BHQ880) as a potential therapeutic agent for multiple
myeloma,” Blood, vol. 114, no. 2, pp. 371–379, 2009.
[71] S. Lotinun, R. S. Pearsall, M. V. Davies et al., “A soluble activin
receptor Type IIA fusion protein (ACE-011) increases bone
mass via a dual anabolic-antiresorptive eﬀect in Cynomolgus
monkeys,” Bone, vol. 46, no. 4, pp. 1082–1088, 2010.
[72] S. Vallet, S. Mukherjee, N. Vaghela et al., “Restoration of
bone balance via activin a inhibition results in anti-myeloma
activity,” Blood, vol. 114, article 645, 2008.
[73] J. Ruckle, M. Jacobs, W. Kramer et al., “Single-dose, ran-
domized, double-blind, placebo-controlled study of ACE-011
(ActRIIA-IgGl) in postmenopausal women,” Journal of Bone
and Mineral Research, vol. 24, no. 4, pp. 744–752, 2009.
[74] K. Podar and K. C. Anderson, “Inhibition of VEGF signaling
pathways in multiple myeloma and other malignancies,” Cell
Cycle, vol. 6, no. 5, pp. 538–542, 2007.14 Bone Marrow Research
[75] N. Ferrara, K. J. Hillan, and W. Novotny, “Bevacizumab
(Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy,” Biochemical and Biophysical Research
Communications, vol. 333, no. 2, pp. 328–335, 2005.
[76] D .H.Gorski,M.A.Beckett,N.T .Jaskowiaketal.,“Blockadeof
thevascularendothelialgrowthfactorstressresponseincreases
the antitumor eﬀects of ionizing radiation,” Cancer Research,
vol. 59, no. 14, pp. 3374–3378, 1999.
[77] R.J.Hoyer,N.Leung,T.E.Witzig,andM.Q.Lacy,“Treatment
of diuretic refractory pleural eﬀusions with bevacizumab in
four patients with primary systemic amyloidosis,” American
Journal of Hematology, vol. 82, no. 5, pp. 409–413, 2007.
[78] B. Goldman, “For investigational targeted drugs, combination
trials pose challenges,” Journal of the National Cancer Institute,
vol. 95, no. 23, pp. 1744–1746, 2003.
[79] A. J. Novak, J. R. Darce, B. K. Arendt et al., “Expression
of BCMA, TACI, and BAFF-R in multiple myeloma: a
mechanism for growth and survival,” Blood, vol. 103, no. 2,
pp. 689–694, 2004.
[80] J. Moreaux, E. Legouﬀe, E. Jourdan et al., “BAFF and APRIL
protect myeloma cells from apoptosis induced by interleukin
6 deprivation and dexamethasone,” Blood, vol. 103, no. 8, pp.
3148–3157, 2004.
[81] Y. T. Tai, X. F. Li, I. Breitkreutz et al., “Role of B-cell-activating
factor in adhesion and growth of human multiple myeloma
cellsinthebonemarrowmicroenvironment,”CancerResearch,
vol. 66, no. 13, pp. 6675–6682, 2006.
[82] J. Moreaux, F. W. Cremer, T. Reme et al., “The level of TACI
gene expression in myeloma cells is associated with a signature
of microenvironment dependence versus a plasmablastic
signature,” Blood, vol. 106, no. 3, pp. 1021–1030, 2005.
[83] J. R. Darce, B. K. Arendt, X. Wu, and D. F. Jelinek, “Regulated
expression of BAFF-binding receptors during human B cell
diﬀerentiation,” Journal of Immunology, vol. 179, no. 11, pp.
7276–7286, 2007.
[84] J. F. Rossi, J. Moreaux, D. Hose et al., “Atacicept in
relapsed/refractorymultiplemyelomaoractiveWaldenstrom’s
macroglobulinemia: a phase I study,” British Journal of Cancer,
vol. 101, no. 7, pp. 1051–1058, 2009.
[85] S.Yaccoby,A.Pennisi,X.Lietal.,“Atacicept(TACI-Ig)inhibits
growth of TACI primary myeloma cells in SCID-hu mice and
in coculture with osteoclasts,” Leukemia,v o l .2 2 ,n o .2 ,p p .
406–413, 2008.
[86] P. Neri, S. Kumar, M. T. Fulciniti et al., “Neutralizing B-
cell-activating factor antibody improves survival and inhibits
osteoclastogenesis in a severe combined immunodeﬁcient
human multiple myeloma model,” Clinical Cancer Research,
vol. 13, no. 19, pp. 5903–5909, 2007.
[87] R. Bellucci, E. P. Alyea, S. Chiaretti et al., “Graft-versus-tumor
response in patients with multiple myeloma is associated
with antibody response to BCMA, a plasma-cell membrane
receptor,” Blood, vol. 105, no. 10, pp. 3945–3950, 2005.
[88] M. C. Ryan, M. Hering, D. Peckham et al., “Antibody targeting
of B-cell maturation antigen on malignant plasma cells,”
Molecular Cancer Therapeutics, vol. 6, no. 11, pp. 3009–3018,
2007.
[89] C. Carlo-Stella, A. Guidetti, M. Di Nicola et al., “IFN-γ
enhances the antimyeloma activity of the fully human anti-
human leukocyte antigen-DR monoclonal antibody 1D09C3,”
Cancer Research, vol. 67, no. 7, pp. 3269–3275, 2007.
[90] E. Sekimoto, S. Ozaki, T. Ohshima et al., “A single-chain
Fv diabody against human leukocyte antigen—a molecules
speciﬁcally induces myeloma cell death in the bone marrow
environment,” Cancer Research, vol. 67, no. 3, pp. 1184–1192,
2007.
[91] I. M. Sainz, I. Isordia-Salas, R. G. Espinola, W. K. Long, R.
A. Pixley, and R. W. Colman, “Multiple myeloma in a murine
syngeneic model: modulation of growth and angiogenesis by
a monoclonal antibody to kininogen,” Cancer Immunology,
Immunotherapy, vol. 55, no. 7, pp. 797–807, 2006.
[92] M. S. Zand, T. Vo, T. Pellegrin et al., “Apoptosis and
complement-mediated lysis of myeloma cells by polyclonal
rabbit antithymocyte globulin,” Blood, vol. 107, no. 7, pp.
2895–2903, 2006.
[93] S. E. Johansson, B. Hejdeman, J. Hinkula et al., “NK cell
activation by KIR-binding antibody 1-7F9 and response to
HIV-infected autologous cells in viremic and controller HIV-
infected patients,” Clinical Immunology, vol. 134, no. 2, pp.
158–168, 2010.
[94] F. Romagne, P. Andre, P. Spee et al., “Preclinical characteriza-
tion of 1-7F9, a novel human anti-KIR receptor therapeutic
antibody that augments natural killer-mediated killing of
tumor cells,” Blood, vol. 114, no. 13, pp. 2667–2677, 2009.
[95] D. M. Benson, F. Romagne, P. Squiban et al., “Novel
monoclonal antibody that enhances natural killer (NK) cell
cytotoxicity against multiple myeloma (MM): preclinical data
and interim phase I clinical trial results,” Journal of Clinical
Oncology, vol. 27, no. 15s, 2009, abstract no. 3032.